A phase II multicenter, open-label study of DB107 in adult patients with newly diagnosed HGG

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jul 2023 New trial record
25 Jul 2023 According to a Denovo Biopharma media release, Noriyuki Kasahara, MD, PhD, is principal Investigator at Brain Tumor Research Center (BTRC) at University of California, San Francisco (UCSF).
25 Jul 2023 According to a Denovo Biopharma media release, the U.S FDA has authorized this phase II trial of DB107 in patients with newly diagnosed high-grade glioma (HGG). Anova Enterprises, Inc. (Anova) will manage the study using its transformative AnovaOS™ technology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com